Developer docs
API playgroundTry for free, no card

Search company profiles

Base4 Biotechnology

Full company profile

uuid0008buw

Namestring
Base4 Biotechnology
Legal namestring
Base4 Biotechnology Inc
Websiteurl
base4.bio
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Base4 Biotechnology is a privately held, Durham, North Carolina-based biotechnology company (founded 2009 as Nymirum, rebranded in 2024) developing RNA-targeted small molecule therapeutics for diseases that have historically been difficult to drug. The company is headquartered in Durham with 11-50 employees and operates as a pre-commercial drug discovery platform rather than a clinical-stage asset company. Its end users are patients with neurodegenerative, neuromuscular, oncological, cardiovascular, immunological, and rare diseases; its direct customers are pharmaceutical partners pursuing co-development and licensing arrangements.

The company's core offering is the VERITAS Platform (Validated Ensembles of RNA Interactions and Targeted AI-enabled Small Molecules), an AI-enhanced, quantum biophysical discovery engine built around its DART (Dynamic Atomic-scale RNA Targets) technology suite. DART leverages powerful NMR observables, machine learning, computational tools, and an internal proprietary database to experimentally determine atomic-resolution ensembles of druggable RNA conformations — not computational models, but experimentally validated structures. VERITAS layers generative AI and combinatorial methods on top of DART to perform multi-billion-scale virtual compound screens in days, identify novel chemotypes, and guide hit-to-lead and lead optimization with atomic-level pocket visibility. The platform claims over 100x enrichment versus conventional screening approaches and is positioned as mechanism-agnostic across microRNAs, mRNA, pre-mRNAs, and repeat expansion RNA.

Base4's business model is enterprise pharma partnering and licensing rather than direct product commercialization. The company runs internal discovery programs while actively seeking strategic collaborations with pharma groups for co-development, generating revenue through licensing and royalty arrangements. Disclosed equity funding totals only ~$3.89M across two early rounds (2009 and 2010), with Hopen Life Science Ventures and Orchard Venture Partners among the named investors; no public funding rounds, named pharma partners, or revenue figures have been disclosed. Co-founders include Dr. Hashim Al-Hashimi (NAS Award in Molecular Biology, 2020), CEO Joshua Fairbank (co-founder of NASDAQ-listed Akebia and Aerpio), and Michael Pape (co-founder of Esperion, sold to Pfizer for $1.3B, and a veteran of Lipitor R&D at Upjohn, Parke-Davis, and Pfizer).

Short descriptiontext

Base4 Biotechnology is a privately held, Durham-based biotech that uses its AI-enhanced VERITAS Platform and DART technology to discover RNA-targeted small molecule therapeutics. It serves pharmaceutical partners through co-development and licensing deals, targeting neurodegenerative, neuromuscular, oncology, cardiovascular, immunological, and rare diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
RNA-targeted drug discovery, small molecule therapeutics, structure-based drug design, AI-enhanced drug screening, quantum biophysical platform
Industry3 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
RNA-targeted Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Partnerships and Licensing
TypeLicensing Royalties
Description

Revenue generated through strategic collaborations with pharma companies for co-development of RNA-targeting therapeutics. The company is developing internal programs while engaging with like-minded pharma groups to accelerate medicine development.

base4.bio
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1VERITAS Platform
Description

AI-enhanced, quantum biophysical discovery platform that resolves dynamic atomic-resolution structures of RNA targets and screens for selective molecules against druggable RNA regions.

base4.bio
+1 more record
Core offering1 text field

Base4 Biotechnology develops RNA-targeted small molecule therapeutics through its proprietary VERITAS Platform, an AI-enhanced quantum biophysical discovery engine. The platform experimentally resolves dynamic atomic-resolution RNA structures using NMR, ML, and GenAI, then performs multi-billion-scale compound screening to identify selective small molecule modulators. The company combines internal drug discovery programs with strategic pharma co-development partnerships to address neurodegenerative, neuromuscular, oncology, cardiovascular, immunology, and rare diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 2 orders of magnitude (100x) enrichment of hits versus conventional screens
Product overview1 text field

Base4 Biotechnology operates as a unified discovery platform built around its VERITAS Platform, which integrates the DART (Dynamic Atomic-scale RNA Targets) technology as its core structural determination engine. VERITAS serves as the AI-enhanced screening and optimization layer, while DART provides the atomic-resolution RNA conformational data that enables structure-based drug discovery. The company applies this integrated platform to develop RNA-targeting small molecule therapeutics across multiple disease areas including oncology, neurology, neuromuscular, cardiovascular, immunology, and rare diseases.

Product and service1 record
1VERITAS Platform
CategoryRNA-targeted Drug Discovery Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arrakis is a direct competitor developing RNA-targeted small molecule therapeutics. Both companies pursue structure-based discovery of selective binders against RNA targets via proprietary platforms, targeting similar disease areas and competing for the same pharma partnership capital.

TypeDirect peer
Description

Ribometrix discovers small molecule drugs that modulate RNA structure and function, including splicing and translation control. It overlaps directly with Base4's VERITAS platform in mechanism and target class, pursuing pharma partnerships for pipeline advancement.

TypeDirect peer
Description

Skyhawk uses its SkySTAR platform to discover small molecules that modify RNA splicing, with major pharma partnerships (e.g., Vertex, Merck). It is a well-capitalized direct peer in RNA-targeted small molecule discovery with a partnership-driven business model like Base4's.

4Expansion Therapeutics
TypeDirect peer
Description

Expansion Therapeutics focuses on small molecule therapeutics for repeat expansion diseases, an explicit focus area cited by Base4 (repeat expansion RNA). Both companies apply structure-informed design to RNA targets in neurological and rare diseases.

TypeDirect peer
Description

Remix is developing small molecules that modulate RNA processing, including splicing, with a data-driven discovery engine. It overlaps with Base4's platform in targeting RNA processing mechanisms and pursuing oncology and rare disease indications.

TypeDirect peer
Description

Accent develops small molecule therapies targeting RNA-modifying proteins (e.g., METTL3). It is a direct peer in RNA-targeted small molecule drug discovery with overlapping oncology focus and a similar partnership-driven model.

TypeEmerging player
Description

Atomic AI uses AI and structural biology to predict RNA 3D structures and identify small molecule binders, paralleling Base4's AI-enhanced, structure-based approach. It represents an emerging competitor combining deep learning with RNA structural resolution.

TypeEmerging player
Description

Shape Therapeutics is an RNA-focused platform company combining RNA biology, structural biology, and AI/ML across modalities. It is an emerging player with thematic overlap to Base4's AI/RNA platform thesis, though broader in modality scope.

TypeBroad incumbent
Description

Denali is a larger, publicly traded biotech developing therapeutics for neurodegenerative and rare diseases — a primary focus area for Base4. It operates more broadly with multiple modalities, including small molecules and biologics, serving as a comparable end-market incumbent.

TypeOthers
Description

Prelude is a clinical-stage precision oncology company using a discovery engine to develop small molecule therapies. It shares a structure-based small molecule discovery philosophy and pharma partnership orientation with Base4, though it is in a more advanced development stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Base4 Biotechnology

RNA-targeted Drug Discoverybase4.bio

Base4 Biotechnology is a privately held, Durham-based biotech that uses its AI-enhanced VERITAS Platform and DART technology to discover RNA-targeted small molecule therapeutics. It serves pharmaceutical partners through co-development and licensing deals, targeting neurodegenerative, neuromuscular, oncology, cardiovascular, immunological, and rare diseases.

What Base4 Biotechnology does

Base4 Biotechnology is a privately held, Durham, North Carolina-based biotechnology company (founded 2009 as Nymirum, rebranded in 2024) developing RNA-targeted small molecule therapeutics for diseases that have historically been difficult to drug. The company is headquartered in Durham with 11-50 employees and operates as a pre-commercial drug discovery platform rather than a clinical-stage asset company. Its end users are patients with neurodegenerative, neuromuscular, oncological, cardiovascular, immunological, and rare diseases; its direct customers are pharmaceutical partners pursuing co-development and licensing arrangements.

The company's core offering is the VERITAS Platform (Validated Ensembles of RNA Interactions and Targeted AI-enabled Small Molecules), an AI-enhanced, quantum biophysical discovery engine built around its DART (Dynamic Atomic-scale RNA Targets) technology suite. DART leverages powerful NMR observables, machine learning, computational tools, and an internal proprietary database to experimentally determine atomic-resolution ensembles of druggable RNA conformations — not computational models, but experimentally validated structures. VERITAS layers generative AI and combinatorial methods on top of DART to perform multi-billion-scale virtual compound screens in days, identify novel chemotypes, and guide hit-to-lead and lead optimization with atomic-level pocket visibility. The platform claims over 100x enrichment versus conventional screening approaches and is positioned as mechanism-agnostic across microRNAs, mRNA, pre-mRNAs, and repeat expansion RNA.

Base4's business model is enterprise pharma partnering and licensing rather than direct product commercialization. The company runs internal discovery programs while actively seeking strategic collaborations with pharma groups for co-development, generating revenue through licensing and royalty arrangements. Disclosed equity funding totals only ~$3.89M across two early rounds (2009 and 2010), with Hopen Life Science Ventures and Orchard Venture Partners among the named investors; no public funding rounds, named pharma partners, or revenue figures have been disclosed. Co-founders include Dr. Hashim Al-Hashimi (NAS Award in Molecular Biology, 2020), CEO Joshua Fairbank (co-founder of NASDAQ-listed Akebia and Aerpio), and Michael Pape (co-founder of Esperion, sold to Pfizer for $1.3B, and a veteran of Lipitor R&D at Upjohn, Parke-Davis, and Pfizer).

Base4 Biotechnology firmographics

Firmographics
Name
Base4 Biotechnology
Legal name
Base4 Biotechnology Inc
Website
https://base4.bio
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Base4 Biotechnology is a privately held, Durham-based biotech that uses its AI-enhanced VERITAS Platform and DART technology to discover RNA-targeted small molecule therapeutics. It serves pharmaceutical partners through co-development and licensing deals, targeting neurodegenerative, neuromuscular, oncology, cardiovascular, immunological, and rare diseases.
Ownership category
akta.pro rank

Base4 Biotechnology industry classification

Industry
Product category
RNA-targeted Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • RNA-targeted drug discovery
  • Small molecule therapeutics
  • Structure-based drug design
  • AI-enhanced drug screening
  • Quantum biophysical platform

Where Base4 Biotechnology is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

Base4 Biotechnology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnerships and Licensing: Revenue generated through strategic collaborations with pharma companies for co-development of RNA-targeting therapeutics. The company is developing internal programs while engaging with like-minded pharma groups to accelerate medicine development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Base4 Biotechnology product offering

Product offering

Core offering

Base4 Biotechnology develops RNA-targeted small molecule therapeutics through its proprietary VERITAS Platform, an AI-enhanced quantum biophysical discovery engine. The platform experimentally resolves dynamic atomic-resolution RNA structures using NMR, ML, and GenAI, then performs multi-billion-scale compound screening to identify selective small molecule modulators. The company combines internal drug discovery programs with strategic pharma co-development partnerships to address neurodegenerative, neuromuscular, oncology, cardiovascular, immunology, and rare diseases.

Product overview

Base4 Biotechnology operates as a unified discovery platform built around its VERITAS Platform, which integrates the DART (Dynamic Atomic-scale RNA Targets) technology as its core structural determination engine. VERITAS serves as the AI-enhanced screening and optimization layer, while DART provides the atomic-resolution RNA conformational data that enables structure-based drug discovery. The company applies this integrated platform to develop RNA-targeting small molecule therapeutics across multiple disease areas including oncology, neurology, neuromuscular, cardiovascular, immunology, and rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • VERITAS Platform: AI-enhanced, quantum biophysical discovery platform that resolves dynamic atomic-resolution structures of RNA targets and screens for selective molecules against druggable RNA regions.
  • DART Platform

Products and services

  • VERITAS Platform

Quantifiable outcome

  • Over 2 orders of magnitude (100x) enrichment of hits versus conventional screens

Companies that use Base4 Biotechnology

Customer profile

Segments1 record

Ideal customer profiles1 record

Base4 Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Base4 Biotechnology partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Base4 Biotechnology competitors and assessment

Company assessment

Direct peers

  • Arrakis Therapeutics: Arrakis is a direct competitor developing RNA-targeted small molecule therapeutics. Both companies pursue structure-based discovery of selective binders against RNA targets via proprietary platforms, targeting similar disease areas and competing for the same pharma partnership capital.
  • Ribometrix: Ribometrix discovers small molecule drugs that modulate RNA structure and function, including splicing and translation control. It overlaps directly with Base4's VERITAS platform in mechanism and target class, pursuing pharma partnerships for pipeline advancement.
  • Skyhawk Therapeutics: Skyhawk uses its SkySTAR platform to discover small molecules that modify RNA splicing, with major pharma partnerships (e.g., Vertex, Merck). It is a well-capitalized direct peer in RNA-targeted small molecule discovery with a partnership-driven business model like Base4's.
  • Expansion Therapeutics: Expansion Therapeutics focuses on small molecule therapeutics for repeat expansion diseases, an explicit focus area cited by Base4 (repeat expansion RNA). Both companies apply structure-informed design to RNA targets in neurological and rare diseases.
  • Remix Therapeutics: Remix is developing small molecules that modulate RNA processing, including splicing, with a data-driven discovery engine. It overlaps with Base4's platform in targeting RNA processing mechanisms and pursuing oncology and rare disease indications.
  • Accent Therapeutics: Accent develops small molecule therapies targeting RNA-modifying proteins (e.g., METTL3). It is a direct peer in RNA-targeted small molecule drug discovery with overlapping oncology focus and a similar partnership-driven model.

Emerging players

  • Atomic AI: Atomic AI uses AI and structural biology to predict RNA 3D structures and identify small molecule binders, paralleling Base4's AI-enhanced, structure-based approach. It represents an emerging competitor combining deep learning with RNA structural resolution.
  • Shape Therapeutics: Shape Therapeutics is an RNA-focused platform company combining RNA biology, structural biology, and AI/ML across modalities. It is an emerging player with thematic overlap to Base4's AI/RNA platform thesis, though broader in modality scope.

Broad incumbents

  • Denali Therapeutics: Denali is a larger, publicly traded biotech developing therapeutics for neurodegenerative and rare diseases — a primary focus area for Base4. It operates more broadly with multiple modalities, including small molecules and biologics, serving as a comparable end-market incumbent.

Others

  • Prelude Therapeutics: Prelude is a clinical-stage precision oncology company using a discovery engine to develop small molecule therapies. It shares a structure-based small molecule discovery philosophy and pharma partnership orientation with Base4, though it is in a more advanced development stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Base4 Biotechnology social profiles

Digital presence

Base4 Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Base4 Biotechnology leadership team

Management profile

Number of profiles

Profiles5 records

Base4 Biotechnology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Base4 Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Base4 Biotechnology

What does Base4 Biotechnology do?

Base4 Biotechnology develops RNA-targeted small molecule therapeutics through its proprietary VERITAS Platform, an AI-enhanced quantum biophysical discovery engine. The platform experimentally resolves dynamic atomic-resolution RNA structures using NMR, ML, and GenAI, then performs multi-billion-scale compound screening to identify selective small molecule modulators. The company combines internal drug discovery programs with strategic pharma co-development partnerships to address neurodegenerative, neuromuscular, oncology, cardiovascular, immunology, and rare diseases.

Is Base4 Biotechnology a public or private company?

Base4 Biotechnology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Base4 Biotechnology founded?

Base4 Biotechnology was founded in 2009. It employs 1 to 10 people.

Where is Base4 Biotechnology based?

Base4 Biotechnology is headquartered in Durham, United States, in the North America region.

How does Base4 Biotechnology make money?

One revenue line is on record: pharmaceutical Partnerships and Licensing.

Who are Base4 Biotechnology's main competitors?

Direct peers on record are Arrakis Therapeutics, Ribometrix, Skyhawk Therapeutics, Expansion Therapeutics, Remix Therapeutics and Accent Therapeutics. Emerging players are Atomic AI and Shape Therapeutics. Denali Therapeutics is listed as a broad incumbent. Prelude Therapeutics is listed as an others.

Does Base4 Biotechnology have an API?

No public API is recorded for Base4 Biotechnology.

What industry is Base4 Biotechnology in?

Base4 Biotechnology's product category is RNA-targeted Drug Discovery. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales